RNA
Price:
$12.83
Market Cap:
$199.06M
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Industry
Biotechnology
IPO Date
2026-02-27
Stock Exchange
NASDAQ
Ticker
RNA
According to Atrium Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.86. This represents a change of 164.08% compared to the average of -1.08 of the last 4 quarters.
The mean historical PE Ratio of Atrium Therapeutics, Inc. over the last ten years is -3.29. The current -2.86 PE Ratio has changed 8.59% with respect to the historical average. Over the past ten years (40 quarters), RNA's PE Ratio was at its highest in in the September 2025 quarter at 0. The PE Ratio was at its lowest in in the December 2025 quarter at -2.17.
Average
-3.29
Median
-3.29
Minimum
-3.29
Maximum
-3.29
Discovering the peaks and valleys of Atrium Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -3.29
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -3.29
| Year | PE Ratio | Change |
|---|
The current PE Ratio of Atrium Therapeutics, Inc. (RNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.29
5-year avg
-3.29
10-year avg
-3.29
Atrium Therapeutics, Inc.’s PE Ratio is
| Company | PE Ratio | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atrium Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Atrium Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Atrium Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Atrium Therapeutics, Inc. (RNA)?
What is the highest PE Ratio for Atrium Therapeutics, Inc. (RNA)?
What is the 3-year average PE Ratio for Atrium Therapeutics, Inc. (RNA)?
What is the 5-year average PE Ratio for Atrium Therapeutics, Inc. (RNA)?
How does the current PE Ratio for Atrium Therapeutics, Inc. (RNA) compare to its historical average?